A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study
Marina Kawaguchi‐Suzuki, Fernando Bril, Paola Portillo-Sánchez et al. · Journal of Chromatography B · 2014
Cited by 13 works. doi:10.1016/j.jchromb.2014.08.019
Authors
References
- Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules
- Thiazolidinediones and PPARγ agonists: time for a reassessment
- Clinical pharmacokinetics of pioglitazone
- High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine
- Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC–MS/MS
- The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
- Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction
- Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study
- High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study
- Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro : Potential for Interactions with CYP2C8 Inhibitors